September 16, 2014 7:04 PM ET

Pharmaceuticals

Company Overview of Shire Human Genetic Therapies Inc.

Company Overview

Shire Human Genetic Therapies Inc., a biopharmaceutical company, develops, and commercializes therapeutics for the treatment of genetic diseases caused by protein deficiencies. The company markets and sells Replagal, an enzyme replacement therapy for the long-term treatment of patients with Fabry disease, in 34 countries outside the United States. The company’s primary clinical programs include iduronate-2-sulfatase, an enzyme replacement therapy for the treatment of hunter syndrome, which is in phase III clinical trials; and Gene-Activated glucocerebrosidase, an enzyme replacement therapy for the treatment of Gaucher disease, which is in phase I/ II clinical trials. In addition, the company...

700 Main Street

Cambridge, MA 02139

United States

Founded in 1988

400 Employees

Phone:

617-349-0200

Fax:

617-613-4004

Key Executives for Shire Human Genetic Therapies Inc.

President
Age: 53
Advisor and Director
Age: 65
Senior Vice President of Manufacturing and Operations
Age: 71
Senior Vice President of Strategic Product Development
Age: 53
Senior Vice President of Human Resources and Corporate Services
Compensation as of Fiscal Year 2014.

Shire Human Genetic Therapies Inc. Key Developments

Shire Human Genetic Therapies Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 02:00 PM

Shire Human Genetic Therapies Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 02:00 PM. Venue: Westin Copley Place, Boston, Massachusetts, United States. Speakers: Jennifer A. King PhD, MBA, Senior Director, Scientific Licensing Business Development.

Shire Human Genetic Therapies Inc. Appoints Frederic Chereau as Senior Vice President and Franchise Lead, Angioedema

Shire plc announced the appointment of Frederic Chereau as Senior Vice President and Franchise Lead, Angioedema, for its Shire Human Genetic Therapies Inc. In this role, Frederic will oversee the development and execution of the global strategy for the angioedema franchise. Frederic was previously President and CEO of Pervasis Therapeutics.

Similar Private Companies By Industry

Company Name Region
HealthAsure, Inc. United States
Inotek Pharmaceuticals Corporation United States
Neuronex, Inc. United States
Helsinn Therapeutics (U.S.), Inc. United States
InfoQuest Clinical Network, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Shire Human Genetic Therapies Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.